Abstract: A preventative mouthwash includes doxycycline as an active ingredient, and sufficient solvent (such as purified water) to dissolve an antimicrobial oral dosage of the doxycycline into a gargling dosage of the mouthwash. The antimicrobial oral dosage may be at least 100 milligrams (mg) of the doxycycline (such as 400 mg). The gargling dosage may be between 5 milliliters (mL) and 20 mL of the mouthwash (such as 5 mL). The mouthwash may further include a flavoring agent (such as benzaldehyde) to improve taste. A method of preventing COVID infection includes gargling the preventative mouthwash, and repeating the gargling twice a day (such as every 12 hours) for several (such as between 5 and 10, like 7) consecutive days. A method of formulating the preventative mouthwash includes dissolving doxycycline hyclate in purified water to create a liquid solution, and dissolving a flavoring agent in the liquid solution to create the mouthwash.

Abstract: A preventative mouthwash includes doxycycline as an active ingredient, and sufficient solvent (such as distilled or purified water) to dissolve a sub-antimicrobial oral dosage (such as between 1 and 40 milligrams) of the doxycycline into a gargling dosage (such as between 5 and 20 milliliters) of the mouthwash. The mouthwash may further include a flavoring agent (such as benzaldehyde) to improve taste. A method of preventing COVID infection includes gargling the preventative mouthwash, and repeating the gargling twice a day (such as every 12 hours) for several (such as between 5 and 10, like 7) consecutive days. A method of formulating the preventative mouthwash includes dissolving doxycycline hyclate in purified water to create a liquid solution having doxycycline as an active ingredient, and dissolving a flavoring agent in the liquid solution to create the mouthwash. Here, a gargling dosage of the mouthwash contains a sub-antimicrobial oral dosage of the doxycycline.

Abstract: A topical formulation for transdermal delivery of sub-acute does of doxycycline hyclate to treat pain and inflammation may include: a base suspension; and doxycycline hyclate. The doxycycline hyclate is mixed with the base suspension in a proportion such that the formulation lacks any antibiotic effect and the concentration of doxycycline hyclate is between 200 and 600 mg/g inclusive. A method of applying the formulation is also disclosed.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A topical formulation for transdermal delivery of sub-acute does of doxycycline hyclate to treat pain and inflammation may include: a base suspension; and doxycycline hyclate. The doxycycline hyclate is mixed with the base suspension in a proportion such that the formulation lacks any antibiotic effect and the concentration of doxycycline hyclate is between 200 and 600 mg/g inclusive. A method of applying the formulation is also disclosed.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A topical formulation for transdermal delivery of sub-acute does of doxycycline hyclate to treat pain and inflammation may include: a base suspension; and doxycycline hyclate. The doxycycline hyclate is mixed with the base suspension in a proportion such that the formulation lacks any antibiotic effect and the concentration of doxycycline hyclate is between 200 and 600 mg/g inclusive. A method of applying the formulation is also disclosed.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A topical formulation for transdermal delivery of sub-acute does of doxycycline hyclate to treat pain and inflammation may include: a base suspension; and doxycycline hyclate. The doxycycline hyclate is mixed with the base suspension in a proportion such that the formulation lacks any antibiotic effect and the concentration of doxycycline hyclate is between 200 and 600 mg/g inclusive. A method of applying the formulation is also disclosed.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A device designed to help people from forgetting objects in vehicles. The device includes a central unit, a power cable, and a conducting insert that closes a circuit. The central unit includes a. case that houses the circuit with an internal power source, a buzzer, a switch, and a relay. The circuit is disconnected and when the conducting insert is inserted, it bridges the switch and completes the circuit. The power cable has a plug on one end and a car charger plug on the other. When the vehicle is running and the car charger plug is plugged into the cigarette charger socket, the plug is powered. When the plug is plugged into the relay in powering mode, the circuit is opened. If the plug is in non-powering mode, the relay will remained closed and the circuit will remain completed at this point.

Abstract: A device designed to help people from forgetting objects in vehicles. The device includes a central unit, a power cable, and a conducting insert that closes a circuit. The central unit includes a. case that houses the circuit with an internal power source, a buzzer, a switch, and a relay. The circuit is disconnected and when the conducting insert is inserted, it bridges the switch and completes the circuit. The power cable has a plug on one end and a car charger plug on the other. When the vehicle is running and the car charger plug is plugged into the cigarette charger socket, the plug is powered. When the plug is plugged into the relay in powering mode, the circuit is opened. If the plug is in non-powering mode, the relay will remained closed and the circuit will remain completed at this point.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.

Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.